Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary fibrosis, a chronic lung-scarring disease, after a mid-stage trial failed to meet its main goal.
No comments yet.
Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary fibrosis, a chronic lung-scarring disease, after a mid-stage trial failed to meet its main goal.
No comments yet.
Log in or sign up to comment.